The vaccine’s success bolsters hope that mRNA vaccines and individualized cancer-targeting medicines could offer a new paradigm for cancer therapies: arstechnica.visitlink.me/Jwu695
arstechnica.visitlink.meModerna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%Markers released top-line results today after previously reporting the trial succeeded.
114 reposts307 likes